3/21/2006 – Vanda Pharmaceuticals Inc., which is developing small molecule product candidates for central nervous system disorders, said it has set the terms of its initial public offering of 5.75 million common shares at $12 to $14 per share.
3/21/2006 – Vanda Pharmaceuticals Inc., which is developing small molecule product candidates for central nervous system disorders, said it has set the terms of its initial public offering of 5.75 million common shares at $12 to $14 per share.
